Opinion|Videos|January 16, 2025
Building Physician-Patient Trust to Increase Timely Screening Rates
Author(s)Kameelah Phillips, MD, FACOG, NCMP
Kameelah Phillips, MD, FACOG, NCMP, discusses how health care providers (HCPs) can empower patients to advocate for their health during cervical cancer and sexually transmitted infection (STI) screenings by building trust, fostering open communication about sensitive topics, and striking a balance between sensitivity and thorough screening practices.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What steps can HCPs take to help educate and build the confidence of their patients to advocate for their own health during visits focused on cervical cancer and STI screenings?
- How can HCPs build a trusting relationship with their patients to facilitate open discussions about sensitive topics like cervical cancer and STI screenings?
- How can HCPs balance the need for sensitivity with the importance of thorough screening practices?
Advertisement
Related to this article
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.
This FAQ summarizes a Special Report discussion on off-label testosterone dosing, application, cost, and lab monitoring in women.
This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
FAQ: How is off-label testosterone dosed and monitored in women?
3
Q&A: Soma Mandal, MD, MSCP, on FDA boxed warning removals for MHT
4
FAQ: What does the evidence show about testosterone in women?
5